Recurrent Acute Myeloid Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-05
Apr 5, 2022
N
Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
  • +6 more
2022-03-31
Mar 31, 2022
M
Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +10 more
  • Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-30
Mar 30, 2022
F
Recruiting
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
N
Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
2022-03-25
Mar 25, 2022
N
Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Los Angeles, California
  • +3 more
2022-03-25
Mar 25, 2022
M
Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +5 more
  • Akt/ERK Inhibitor ONC201
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-10
Mar 10, 2022
N
Recruiting
  • Previously Treated Myelodysplastic Syndrome
  • +7 more
  • Duarte, California
  • +10 more
2022-03-22
Mar 22, 2022
M
Active, not recruiting
  • FLT3 Gene Mutation Negative
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-18
Mar 18, 2022
B
Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Portland, Oregon
  • +1 more
2022-03-18
Mar 18, 2022
F
Recruiting
  • Recurrent Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-07
Mar 7, 2022
M
Completed
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +8 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-16
Mar 16, 2022
M
Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
M
Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
B
Recruiting
  • Acute Myeloid Leukemia
  • Recurrent Acute Myeloid Leukemia
  • Los Angeles, California
  • +2 more
2022-03-11
Mar 11, 2022
M
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
C
Not yet recruiting
  • Recurrent Acute Myeloid Leukemia
  • Bosutinib Monohydrate
  • +6 more
  • Duarte, California
    City of Hope Meidcal Center
2022-03-07
Mar 7, 2022
C
Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
M
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +25 more
  • Allogeneic Natural Killer Cell Line NK-92
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
C
Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-21
Feb 21, 2022
F
Recruiting
  • Acute Lymphoblastic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-25
Feb 25, 2022
R
Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-02-25
Feb 25, 2022